Free Trial
NASDAQ:SLRX

Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis

Salarius Pharmaceuticals logo
$1.44 +0.04 (+2.86%)
(As of 11/21/2024 ET)

About Salarius Pharmaceuticals Stock (NASDAQ:SLRX)

Key Stats

Today's Range
$1.40
$1.48
50-Day Range
$1.29
$2.01
52-Week Range
$1.26
$7.27
Volume
34,531 shs
Average Volume
772,805 shs
Market Capitalization
$2.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Salarius Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
2nd Percentile Overall Score

SLRX MarketRank™: 

Salarius Pharmaceuticals scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Salarius Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Salarius Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Salarius Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Salarius Pharmaceuticals has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.64% of the float of Salarius Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Salarius Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Salarius Pharmaceuticals has recently increased by 4,233.33%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Salarius Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Salarius Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.64% of the float of Salarius Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Salarius Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Salarius Pharmaceuticals has recently increased by 4,233.33%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 1 people have searched for SLRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.38% of the stock of Salarius Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 11.88% of the stock of Salarius Pharmaceuticals is held by institutions.

  • Read more about Salarius Pharmaceuticals' insider trading history.
Receive SLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SLRX Stock News Headlines

JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Salarius Pharmaceuticals Inc.
See More Headlines

SLRX Stock Analysis - Frequently Asked Questions

Salarius Pharmaceuticals' stock was trading at $5.20 at the beginning of the year. Since then, SLRX shares have decreased by 72.3% and is now trading at $1.44.
View the best growth stocks for 2024 here
.

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) posted its quarterly earnings results on Friday, August, 9th. The company reported ($2.37) earnings per share for the quarter, topping the consensus estimate of ($53.60) by $51.23.

Shares of Salarius Pharmaceuticals reverse split on the morning of Monday, June 17th 2024. The 1-8 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Salarius Pharmaceuticals investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Meta Platforms (META), T2 Biosystems (TTOO), NIO (NIO) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
8/09/2024
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLRX
Fax
N/A
Employees
20
Year Founded
2011

Profitability

Net Income
$-12,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.84 million
Book Value
$2.03 per share

Miscellaneous

Free Float
1,421,000
Market Cap
$2.07 million
Optionable
Not Optionable
Beta
0.93

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:SLRX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners